Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Rotavirus VP7 glycoprotein (G9 type) is a major structural protein located on the outer shell of the rotavirus virion. It is a calcium-binding protein that plays a critical role in the initial stages of viral infection, specifically in the attachment and penetration of host intestinal cells. As the primary determinant of the G-serotype, VP7 is a major target for the host's neutralizing antibody response. The G9 serotype has emerged globally as one of the most prevalent strains causing severe diarrhea in children. Therapeutic strategies primarily involve preventive vaccines that utilize live-attenuated strains expressing G9 or other common VP7 types to elicit protective immunity. Vaccines like Rotavac and Rotasiil specifically incorporate the G9 antigen to provide broad protection against circulating strains. Understanding the structural variations in the G9 type is essential for monitoring vaccine efficacy and the emergence of escape mutants.
Induction of neutralizing antibodies that bind to the VP7 glycoprotein, blocking viral attachment to host cells and preventing the calcium-dependent uncoating of the viral particle.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Rotavirus A VP7 glycoprotein (G9 type) (VP7).